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Simple Summary: High-dose methotrexate is commonly used to treat several types of cancer. While
effective, elimination of high-dose methotrexate from the body is highly variable and delayed
elimination can lead to serious and sometime life-threatening adverse events. There have been
many clinical studies to better understand how genetics influence the variability in methotrexate
elimination, mostly through candidate gene studies and three genome-wide association studies.
Unfortunately, there are conflicting results and some studies lack the appropriate replication and
validation needed to confirm their effects on methotrexate elimination. Therefore, the purpose of
this systematic review was to summarize all of the germline pharmacogenetic association studies of
genetic associations influencing high-dose methotrexate elimination in children with cancer.
Abstract: Methotrexate (MTX) is a mainstay therapeutic agent administered at high doses for the treatment
of pediatric and adult malignancies, such as acute lymphoblastic leukemia, osteosarcoma, and lymphoma.
Despite the vast evidence for clinical efficacy, high-dose MTX displays significant inter-individual pharma-
cokinetic variability. Delayed MTX clearance can lead to prolonged, elevated exposure, causing increased
risks for nephrotoxicity, mucositis, seizures, and neutropenia. Numerous pharmacogenetic studies have
investigated the effects of several genes and polymorphisms on MTX clearance in an attempt to better
understand the pharmacokinetic variability and improve patient outcomes. To date, several genes and
polymorphisms that affect MTX clearance have been identified. However, evidence for select genes have
conflicting results or lack the necessary replication and validation needed to confirm their effects on MTX
clearance. Therefore, we performed a systematic review to identify and then summarize the pharma-
cogenetic factors that influence high-dose MTX pharmacokinetics in pediatric malignancies. Using the
PRISMA guidelines, we analyzed 58 articles and 24 different genes that were associated with transporter
pharmacology or the folate transport pathway. We conclude that there is only one gene that reliably
demonstrates an effect on MTX pharmacokinetics: SLCO1B1.
Keywords: methotrexate; pharmacokinetics; pharmacogenetics; pediatrics; acute lymphoblastic
leukemia; osteosarcoma; lymphoma
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1. Introduction
Methotrexate (MTX) is a folate analog that has long been administered at high doses
to effectively treat pediatric and adult malignancies such as acute lymphoblastic leukemia
(ALL), lymphoma, and osteosarcoma [1–5]. MTX, in its polyglutamated form, is an ef-
fective chemotherapeutic agent that competitively inhibits the dihydrofolate reductase,
a key enzyme responsible for the reduction reaction of dihydrofolate to tetrahydrofo-
late [6]. Such inhibition drains the cells of necessary tetrahydrofolate, thus disrupting
the de novo biosynthesis of purines and pyrimidines and preventing the formation of
necessary one-carbon donors needed for DNA methylation [7]. High-dose MTX has con-
tributed to the dramatically increased survival rates for pediatric patients with ALL [8–10].
Despite this improvement, there remains a troubling occurrence of high-dose MTX-induced
toxicities [11,12] that often results from variability in MTX pharmacokinetics (PK). Numer-
ous clinical studies have investigated this variability in MTX PK in relation to treatment
response or toxicity. Since protocols with high-dose MTX treatment include frequent
monitoring, extensive amounts of clinical data are often collected during each patients’
treatment. Tests of renal function are of particular importance, given that MTX is primarily
renally eliminated [11]. A decrease or delay in MTX elimination as a result of damage to the
renal tubules can cause prolonged systemic exposure to MTX. Renal dysfunction can cause
a subsequent reduction in both renal absorption and elimination of MTX [11,12]. Con-
versely, the liver plays a key role in the metabolic conversion of MTX into 7-hydroxyMTX
by aldehyde oxidase. However, in high-dose MTX infusions, reports indicate that 55–80%
of MTX is eliminated as unchanged drug in the urine [13]. Hepatic elimination of MTX is
only estimated to account for 10% of MTX elimination [14].
PK findings from clinical studies can lead to improvements in therapeutic outcomes
through amendments to clinical protocols [5,15] or the development of clinical decision
support tools [16]. It was recently shown that >90% of persons have an actionable drug-gene
polymorphism [17,18]. A plethora of clinical studies have been including pharmacogenetics
in an effort to describe more of the variability in MTX PK and improve therapeutic outcomes.
To date, pharmacogenetic studies have identified several genes that contribute to the vast
variability in MTX PK and primarily fall under folate pathway genes (MTHFR, MTR, MTRR,
and DHFR) or PK/transporter genes (SLCO1B1, SLC19A1, OAT1, and OAT3). However,
trying to use these data in a clinically meaningful way can be challenging due to the
sheer volume of pharmacogenetic data that exist. Additionally, there is inconsistent and
contrasting evidence available for some genes and genetic variants, which can complicate
their clinical utility, while others lack the appropriate replication and validation needed
to be reliable predictors of MTX PK. A great resource that catalogs the pharmacogenetic
literature is the Pharmacogenomics Knowledge Base (www.pharmgkb.org, accessed on
27 May 2021), but for MTX, it does not readily distinguish between high-dose and low-
dose indications, where we know the dose impacts the PK and pharmacodynamics, and
therefore may have different pharmacogenetic associations.
Therefore, the objective of this systematic review was to identify and then provide a
comprehensive overview of the available pharmacogenetic factors that influence high-dose
MTX PK in pediatric malignancies. Herein, we discuss the use of the PRISMA guidelines
to select and summarize genome-wide association studies and candidate gene studies
that evaluated the association between genetic polymorphisms and MTX PK in pediatric
patients with acute lymphoblastic leukemia, lymphoma, or osteosarcoma.
2. Materials and Methods
2.1. Eligibility Criteria
We used the PRISMA guidelines for systematic review [19]. Studies were included if
they:
• Evaluated the association between genetic polymorphisms and MTX PK;
• Included pediatric patients
• With ALL, lymphoma, or osteosarcoma.
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Studies were excluded if they:
• Only investigated the PK of MTX (no genetics),
• Only investigated the pharmacogenetics of MTX on toxicity (no PK),
• Only investigated patients with other malignancies,
• Did not include pediatric patients (only include adult populations), and
• Were not published in English.
2.2. Search Strategy
We searched PubMed and Scopus on November of 2020 and February of 2021. We
used a combination of keywords and medical subject headings that focused on five key
search criteria: (1) MTX; (2) PK; (3) pharmacogenetics; (4) pediatrics; (5) ALL, lymphoma,
and osteosarcoma. The full list of search queries for PubMed and Scopus can be found in
the Supplementary Materials, Table S1.
2.3. Data Collection
Z.L.T and L.B.R independently assessed the eligibility of the studies by reviewing
abstracts. Full texts were considered on an “as-needed” basis. Conflicts between Z.L.T and
L.B.R were resolved by discussion. Z.L.T extracted data from the included studies using the
available full text: study type (GWAS or candidate gene study), patient population (number
of patients, indication), treatment methods (treatment protocol, dosages, course quantity),
study design (quantification method for MTX, method for genotyping), PK endpoints
(clearance, concentrations at certain times after a dose, delayed MTX elimination), and
genes studied.
2.4. Qualitative Data Analysis
For each article, the selected gene(s) and associated polymorphism(s) was/were noted
along with the primary PK endpoint, and the directionality of the effect. After all included
articles were annotated, Z.L.T determined whether the overall effect of each gene and
associated polymorphisms decreased MTX clearance, increased MTX exposure, and/or
increased MTX concentrations along with a short synopsis of the available, published data.
Articles that presented conflicting evidence were noted and taken into consideration when
determining the overall effect of the gene and polymorphism. Genes were then assigned to
a gene table (transporter or folate pathway), and commonly studied polymorphisms were




Figure 1 shows the PRISMA flow diagram for this literature review. The final PubMed
search performed in February 2021 found 443 articles. The final Scopus search performed in
February 2021 found 492 articles. After duplications were removed, 759 articles remained.
The initial abstract screening process excluded 699 articles. Full-text of the remaining 60
articles were assessed. Upon full-text review, two additional articles were excluded due to
a lack of pharmacogenetic associations with MTX PK, resulting in a final total of 58 articles
for qualitative analysis.
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Figure 1. PRISMA diagram for systematic literature review.
3.2. Study Characteristics
The 58 studies analyzed pharmacogenetic associations on MTX PKs from 9695 pa-
tients. Three studies were GWAS and 55 were candidate gene studies. ALL was the most
commonly studied malignancy, with 51 of the 58 articles reporting on pediatric patients
with ALL, followed by five studies reporting on pediatric patients with osteosarcoma, and
three studies reporting on pediatric patients with lymphoma. One study reported on both
patients with ALL and patients with lymphoma.
Of the reported studies, Sequenom MassARRAY was most commonly used for geno-
typing and fluorescence polarization immunoassay was most commonly used to detect
and quantify MTX concentrations.
3.3. Association between Genetic Polymorphisms and MTX PKs
3.3.1. Transporter Genes
The following information is summarized and presented in Table 1.
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Table 1. Transporter Genes That Significantly Affect Methotrexate Exposure.
Gene Name Variants Effect of Variant onMethotrexate Exposure References
ABCB1 rs9282564 ↑ [20],[21]
ABCG2 rs12505410 ↓ [22]
ABCG2 rs13120400 ↑ [22]
ABCG2 rs13137622 ↓ [22]
ABCG2 rs2231142 ↑ [20],[23–27]
ABCC2 rs3740065 ↑ *|↓ [22],[28],[29]*,[30]*,[31]*
ABCC2 rs3740066 ↑ *|↓ [20],[27]*,[29]*
ABCC2 rs717620 ↑ *|↓ [20,22,23,27–29],[30]*,[31]*,[32],[33–36]
ABCC3 rs4793665 ↓ [20],[36]
ABCC3 rs9895420 ↓ [36]
ABCC4 rs10219913 ↑ [28],[29]
ABCC4 rs7317112 ↑ [28],[29]
ABCC4 rs868853 ↓ [29,31],[37]
ABCC4 rs9516519 ↑ *|↓ [28]*,[29],[31]*
SLC19A1 rs1051266 ↑ *|↓ [20–22],[26]*,[27,28],[29]*,[33–35,38,39],[40]*,[41]*,[42]*,[43]*
SLC19A1 rs1051296 ↑ [44]
SLC19A1 rs61510559 ↓ [23,25],[45],[46,47]
SLCO1A2 rs4149009 ↓ [27,29],[48]
SLCO1B1 rs10841753 ↑ *|↓ [38],[49]*,[50]
SLCO1B1 rs11045787 ↑ [49]
SLCO1B1 rs11045818 ↑ *|↓ [21],[49]*,[50]*
SLCO1B1 rs11045813 ↑ [50]
SLCO1B1 rs11045819 ↓ [21],[51]
SLCO1B1 rs11045821 ↓ [50]
SLCO1B1 rs11045825 ↓ [50]
SLCO1B1 rs11045870 ↓ [50]
SLCO1B1 rs11045872 ↓ [22],[49],[50]
SLCO1B1 rs11045879 ↑ *|↓ [22],[25]*,[29],[33],[35]*,[49],[50]*,[52]
SLCO1B1 rs11045892 ↓ [50]
SLCO1B1 rs11045897 ↑ [38],[53]
SLCO1B1 rs16923647 ↓ [50]
SLCO1B1 rs17328763 ↑ [49]
SLCO1B1 rs2169969 ↓ [50]
SLCO1B1 rs2306283 ↑ *|↓ [27]*,[33],[38],[54]
SLCO1B1 rs2900476 ↓ [22],[49]
SLCO1B1 rs34671512 ↓ [51]
SLCO1B1 rs4149056 ↑ [21],[22,27],[28],[32],[33],[34],[35],[38,43],[49],[50],[51],[52],[54],[55]
SLCO1B1 rs4149076 ↓ [49]
SLCO1B1 rs4149081 ↑ *|↓ [22]*,[49],[50]*,[25]*,[53]*
SLCO1B1 rs59502379 ↑ [51]
Genes and variants not found in the table above do not significantly affect methotrexate exposure. Please see Table S2 in Supplementary for
full list of genes and variants. Underlined references found a significant association between variant and methotrexate exposure. * Indicates
the studies that showed increased MTX exposure when there were conflicting reports for a variant. ↑ Indicates that the variant is associated
with increased/higher methotrexate exposure. ↓ Indicates that the variant is associated with decreased/lower methotrexate exposure.
Cancers 2021, 13, 2837 6 of 20
ABCB1
ATP-binding cassette subfamily B member 1 (ABCB1) encodes an ATP-dependent
drug efflux pump involved in multidrug resistance, which is expressed in liver, kidney and
gastrointestinal tract [56] (Figure 2). The association of polymorphisms in this gene with
MTX PK has been studied in 13 different studies. The most commonly studied SNP was
rs1045642, which was included in eight studies; while four studies identified a decrease
in MTX clearance associated with the rs1045642T allele [25,26,34,57], only one of them
reached the statistical significance threshold [26], and the other four studies did not find an
effect of the SNP [20,27,35,38]. On the other hand, the rs9282564T allele was significantly
associated with MTX AUC and Cmax [20]; however, it was not associated with MTX PK in
the other study in which it was analyzed [21].
Figure 2. Transporter genes involved in methotrexate pharmacology. Transporters of similar function are grouped by shape.
The color scheme for the transporters reflects the number of studies that found a significant pharmacogenetic association
with MTX exposure. BBB: blood–brain barrier; CSF: cerebrospinal fluid; FOLR1: Folate Receptor Alpha; MTX: methotrexate.
ABCG2
ATP-binding cassette subfamily G member 2 (ABCG2) encodes another ATP-binding
cassette (ABC) transporter involved in multidrug resistance and is primarily expressed in
the gastrointestinal tract [56] (Figure 2). Polymorphisms in this gene have been included
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in 13 different studies in order to determine their role in MTX PK. The most frequently
studied SNP was rs2231142, which was analyzed in six studies. The variant A allele was
significantly associated with decreased MTX clearance in two studies [20,26], while the
same directionality was observed in another study, without reaching significance [25], and
no association was identified in the other three studies [23,24,27]. In addition, three SNPs
(rs12505410, rs13120400, and rs13137622) were significantly associated with MTX PK in a
single study [22]. Nevertheless, since this is the only article in which they were studied,
additional studies would be needed to confirm those associations.
ABCC2
ATP-binding cassette subfamily C member 2 (ABCC2) encodes an ABC transporter
involved in multidrug resistance that is highly expressed in liver and kidney, where it
is responsible for the efflux of different drugs [56] (Figure 2). Polymorphisms in this
gene have been analyzed in 16 different studies. Among them, three SNPs (rs717620,
rs3740065, and rs3740066) have been significantly associated with MTX PK but with
conflicting results. The most commonly studied was rs717620, which was included in 13
studies [20,22,23,27–36]. While three of the studies supported an association of the variant
T allele with increased MTX clearance [28,29,32], the other two suggested an association
with decreased MTX clearance [30,31], and the remaining studies did not show any effect.
Similarly, rs3740065 was investigated in five studies [22,28–31], and, while three studies
supported an association of the variant C allele with decreased MTX clearance [29–31],
another study suggested that the variant C allele increased MTX clearance [28]. Finally,
rs3740066 was analyzed in three studies [20,27,29], one of them supporting an association
with increased clearance [20], another showing a non-significant association with decreased
clearance [29], and the remaining reporting no effect.
ABCC3
ATP-binding cassette subfamily C member 3 (ABCC3) is another multidrug resistance
protein that is ubiquitously expressed [56] (Figure 2). Polymorphisms in this gene have
been included in seven different studies. Two SNPs were significantly associated with MTX
PK, rs4793665 [20], which was not associated with MTX PK in the other study in which it
was studied [36], and rs9895420, which was reported in a single study [36].
ABCC4
ATP-binding cassette subfamily C member 4 (ABCC4) is a multidrug resistance protein
from the ABC superfamily. Eight studies have investigated polymorphisms in this gene
in relation to MTX PK. There is moderate evidence to suggest that four SNPs (rs10219913,
rs7317112, rs9516519, and rs868853) might alter MTX clearance. Two studies supported the
association of the rs10219913 variant C allele and the rs7317112 variant G allele with de-
creased MTX clearance [28,29]. Conversely, two of the three studies that analyzed rs868853
supported an association of the C variant allele with increased MTX clearance [31,37].
Finally, regarding rs9516519, three studies have analyzed this SNP [28,29,31]. The variant
G allele was significantly associated with increased clearance one of the studies [29], and a
similar tendency was observed in another one [31].
ABCC1, ABCC5 and ABCC10
ABCC1, ABCC5 and ABCC10 are multi-specific organic anion pumps and part of
the MRP subfamily that are ubiquitously expressed throughout the body [56] (Figure 2).
Polymorphisms in the remaining ABC transporters ABCC1, ABCC5, and ABCC10 have
been studied in seven, four and four studies, respectively. However, none of the studies
reported statistically significant associations with MTX PK.
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SLC19A1
The solute carrier family 19 member 1 or reduced folate carrier 1 is a ubiquitously and
robustly expressed transporter in humans that mediates the uptake of endogenous reduced
folates and anti-folate xenobiotics [56] (Figures 2 and 3). SLC19A1 also plays a key role in
folate homeostasis. Due to its associations with both MTX transport and folate metabolism,
SLC19A1 was highly studied, appearing in 24 gene candidate studies with 20 different SNPs.
Seven of the 24 gene candidate studies found a significant association between SLC19A1 and
MTX PK. The rs1051266 (G80A, formerly known as rs61510559) was the most abundantly
studied and is a common non-synonymous polymorphism resulting in a substitution of a
histidine for an arginine. Of the 21 studies that reported on rs1051266, five studies found a
significant association [40–43,45] with MTX PK. Four of the five reported findings agree
that the variant A allele is associated with decreased MTX clearance. This directionality was
supported by two additional studies [26,29], but both failed to reach their set significance
thresholds. Conversely, several more studies [20–23,25,27,28,33–35,38,39,45–47], including
the aforementioned study [45], demonstrated that the variant A allele is associated with
increased MTX clearance; all but one [45] reported finding of this directionality failed
to reach their set significance thresholds. The rs1131596 variant was reported by two
studies [29,38]. Both studies did not find a significant association between rs1131596 and
MTX PK. Lastly, the rs3788200 variant was reported by two studies [29,38]. Both studies
did not find a significant association between rs378820 and MTX PK. The three GWAS did
not report a significant association between polymorphisms of SLC19A1 and MTX PK.
Figure 3. Folate transport pathway. The color scheme for the folate pathway genes reflects the number of studies
that found a significant pharmacogenetic association with MTX exposure. AICAR: 5-aminoimidazole-4-carboxamide
ribonucleotide; DHF: dihydrofolate; dUMP: deoxyuridine monophosphate; dTMP: deoxythymidine monophosphate;
fAICAR: 5-formamidoimidazole-4-carboxamide ribonucleotide; FOL: folate; Glu: glutamated; FOLH1: N-acetyl-L-aspartyl-
L-glutamate peptidase; I HCOOH: formic acid; MTX: methotrexate; Poly: prefix, meaning more than one, SAM: S-adenosyl
methionine, SAH: S-adenosyl-l-homocysteine; SHMT1: serine hydroxymethyltransferase 1; THF: tetrahydrofolate.
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SLC22A6 and SLCO22A8
The SLC22A6 and SLC22A8 solute carriers encode the organic anion transporters 1
and 3 (OAT1 and OAT3) that facilitate transport of many different organic anions including
urate, probenecid and proton pump inhibitors [58–60]. In vitro studies have confirmed that
the OAT1 and OAT3 transporters have affinity for MTX and that the cellular uptake of MTX
can be inhibited by administration of other organic anions (e.g., probenecid and proton
pump inhibitors) [58–61]. The OAT1 and OAT3 proteins are located on the basolateral
membrane of the renal tubules cells, where they facilitate uptake of MTX from the blood
into the cells [56] (Figure 2). Several non-synonymous SNPs with low allele frequency have
been identified in the coding region of SLC22A8 and shown to alter the in vitro uptake
of MTX but the allele frequencies of these SNPs are low [62]. Animal studies with Oat3
knock-out mice indicate that the Oat3 transporter is involved in the plasma clearance of
MTX and reduced folates but also suggest that this is not the most important route of MTX
elimination [63].
Polymorphisms in SLCO22A6 and SLCO22A8 were not associated with MTX PK in
any of the genome-wide association studies [49–51], and only two candidate gene studies
included SNPs from the two genes [21,29]. Lopez-Lopez et al. found an association
between the 72-h plasma MTX > 0.2 µM and two SLC22A6/SLC22A8 haplotypes but this
was not statistically significant after adjusting for multiple comparisons [29]. In another
candidate gene study, the variant C allele in rs4149183 in SLC22A8 was associated with
renal toxicity (serum creatinine level > 100 µmol/L) but not plasma concentrations of MTX
or 7-OH-MTX [21]. Most of the 15 studied SNPs in the two candidate gene studies were
located in introns or upstream to the genes.
SLCO1A2
The solute carrier organic anion transporter family member 1A2 gene is expressed in
several tissues, including the liver, brain, eye, and proximal digestive tract [56] (Figure 2).
It has been tested for association with MTX clearance in six studies [27,29,48–51] but the
evidence for association is weak.
The two studies directly testing an association between the rs4149009 A allele and
MTX concentration did not find an association [29,48] but one found that patients with
<1 µmol/L MTX at 42 h were enriched for the AA variant genotype compared to GA
and GG patients, suggesting that the variant A allele is associated with increased MTX
clearance. The GWAS found two SNPs in SLCO1A2 reached genome-wide significance, but
likely because they were in LD with SNPs in the neighboring SLCO1B1 gene, not because
they were functionally affecting SLCO1A2 [50].
SLCO1B1
The solute carrier organic anion transporter family member 1B1 gene is nearly ex-
clusively expressed in the liver where it is located at the basolateral membrane of the
hepatocytes [56] (Figure 2). Substrates of the SLCO1B1 (OATP1B1) transporter include
endogenous molecules such as bilirubin and estrogens, as well as drugs, most notably
statins and MTX. Genome-wide association studies identified variants in SLCO1B1 as the
only gene associated with MTX clearance at the usual genome-wide significance thresh-
old [49,50]. In sequencing patients with the fastest and slowest MTX clearance, rare variants
with large effects were identified, and the function was verified in vitro [51]. The SNP
most often tested for association with MTX PK measures is rs4149056, which encodes
a T521C transition that reduces the localization of the transporter to the surface of the
cell and causes a severe reduction in transport of MTX in vitro [64]. This variant was
universally associated with decreased MTX clearance among all the studies included in this
review [21,22,27,28,32–35,38,43,49–52,54,55]. The rs4149056 common variant is included in
two * alleles, the no function *5 (no other coding variants) allele and the more common *15
(with rs2306283 A > G) allele. Other decreased function alleles associated with reduced
MTX clearance and reduced in vitro transport include *23 and *31 [51]. There were also
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alleles associated with increased MTX clearance [51] and transporter expression [65], *14
and *35. The rs2306283 A > G variant is included in many * alleles, and is associated with
increased transporter expression. Most studies found that this SNP associated with faster
MTX clearance [33,54], but one found that it associated with slower clearance [27].
SLCO1B3
The solute carrier organic anion transporter family member 1B3 gene is also exclusively
expressed in the liver [56] (Figure 2) and is located on chromosome 12 next to SLCO1B1.
In vitro studies have shown that it transports MTX [66]. None of the eleven tested variants
in SLCO1B3 influenced the 72 h MTX concentration in one study [29] or reached genome-
wide significance in the GWAS, though two variants were close (p < 3 × 10−6) [49–51].
3.3.2. Folate Pathway Genes
The following information is summarized and presented in Table 2.
Table 2. Folate Pathway Genes That Significantly Affect Methotrexate Exposure.
Gene Name Variants Effect of Variant onMethotrexate Exposure References
ARID5B rs4948496 ↑ [21],[32]
GGH rs3758149 ↑ [20],[67],[68]
FPGS rs1544105 ↓ [69],[70],[67],[21]
MTHFD1 rs2236225 ↓ [21],[35],[71]
MTHFR rs1801133 ↑|↓ * [23],[25],[26],[27,28],[32–35],[39],[42]*,[43,45–47,52],[57],[67],[71]*,[72],[73–77],[78],[79,80]
TYMS rs2790 ↓ [81]
TYMS rs34743033 ↓ [25,33,34],[42],[43,46,57,71]
Genes and variants not found in the table above do not significantly affect methotrexate exposure. Please see Table S2 in Supplementary for
full list of genes and variants. Underlined references found a significant association between variant and methotrexate exposure. * Indicates
the studies that showed decreased MTX exposure when there were conflicting reports for a variant. ↑ Indicates that the variant is associated
with increased/higher methotrexate exposure. ↓ Indicates that the variant is associated with decreased/lower methotrexate exposure.
ATIC
The 5-aminoimidazole-4-carboxamide ribonucleotide transformylase gene (ATIC)
encodes a bifunctional enzyme that catalyzes the last two steps of the de novo purine
pathway’s last two steps [56] (Figure 3). Due to its function as a pharmacodynamic en-
zyme and inclusion in MTXs mechanism of action, ATIC has been included as a candidate
gene. However, three individual genome-wide association studies related to MTX clear-
ance [49–51] did not find any genome-wide significance for ATIC. One study, in particular,
on the polymorphism of ATIC 347 C > G allele concluded the variants had zero influence
in higher 48 h concentrations [45].
ARID5B
ARID5B, encodes a member of the AT-rich interaction domain (ARID) family of DNA-
binding proteins. The protein is widely expressed in most tissue types [56] and is associated
with adipogenesis and liver development. It mainly serves as a transcriptional modulator
and regulates targeted gene expression by recruiting PHD finger protein 2 [82]. This
gene is also involved in cell growth and differentiation of B-lymphocyte progenitors, and
is associated with the incident and relapse of ALL. However, underlying mechanisms
by which ARID5B genotype impacts the susceptibility and treatment outcome remain
uncertain. The current premise is that treatment outcome is related to the cancer cell’s
sensitivity to antimetabolite drugs, including 6-mercaptopurine and MTX.
Five studies included SNPs in ARID5B [21,32,49–51] and only two of these studies
found that SNPs reached the statistical threshold. One article [21] found a significant asso-
ciation linking rs4948496 with MTX concentrations, while the other study [32] was unable
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to find an association between rs4948496 and MTX concentration. This article [21] classified
only the rs4948496 (T to C) variant, for which they found increased MTX concentrations at
time points 24, 36 and 48 h. Both studies do suggest that the CC genotypes are responsible
for decreased MTX clearance. This study also found significant PK associations between
rs4948502 and increased serum concentration of 7-OH-MTX.
DHFR
Dihydrofolate reductase (DHFR) is an enzyme that converts dihydrofolate into tetrahy-
drofolate (Figure 3). The folic acid derivative is required for the de novo synthesis of
purines, thymidylic acid, and several amino acids. The pharmacodynamic target of MTX
is inhibition of DHFR, where the affinity of DHFR for MTX is 1000-fold higher than for
folate. However, the GWAS studies [49–51] and PK studies [27,43,75] did not find evidence
supporting DHFR polymorphisms to be associated with MTX PK.
GGH
Gamma-glutamyl hydrolase or GGH is a lysosomal peptidase that hydrolyzes gamma-
linked polyglutamates on folate derivates, converting long-chain MTX polyglutamates
(MTX-PGs) into a short-chain MTX-PGs and sequentially to MTX (Figure 3). Therefore, the
modulation of GGH may affect the chemosensitivity of cancer cells, and exogenous folate
levels may further modify this effect [56].
Four candidate gene studies examined five GGH polymorphisms (rs11545078, rs11545077,
rs1800909, rs11545076, rs3758149) and MTX PK [20,67,68,83]. The rs3758149 variant (C > T) CT,
and TT genotypes were specifically examined in two additional studies [20,67]. They focused
on the variant due to its higher recurrence rate in patients with MTX serum levels >40 µmol
at 24 h compared to CC wild type and proposed that the variant T allele was associated
with decreased MTX clearance. Although no observable change in 48 h MTX concentration
was found in two studies [20,68], it was significantly associated with MTX concentration in
one [67].
Lastly, there is evidence that the methylation levels of CpG units for the GGH promoter
region 14 affect MTX PK [83].
FPGS
Folylpolyglutamate synthetase (FPGS) is responsible for the conversion of MTX into
MTXPGs (Figure 3). Loss of function leads to reduced intercellular concentration of MTXPG
and results in MTX drug resistance [56]. The variants (rs1544105, rs10106, and rs4451422)
were studied across four studies [21,67,69,70]. Three studies [67,69,70] reported that the
rs1544105 (A to G) variant GG genotype resulted in a non-significant reduction in the 24 h
MTX serum concentration compared to the AA and AG genotypes. One study [70] con-
cluded that the rs1544105 genotype significantly influences the MTX concentration/dose
values at 24 h after start of the high-dose MTX infusion.
MTHFD1
The trifunctional enzyme methylenetetrahydrofolate dehydrogenase (MTHFD1) is highly
expressed in the liver [56]. The enzyme catalyzes tetrahydrofolate reduction in three sequential
reactions of 10-formyltetrahydrofolate 5,10-methylenetetrahydrofolatedehydrogenase/5,10-
methenyltetrahydrofolate-cyclohydrolase/10-formyltetrahydrofolate resulting in the analo-
gous 10-formyl, 5,10-methenyl and 5,10-methylene derivatives (Figure 3). The three deriva-
tives are all part of the one-carbon folate pool and required for biosynthetic processes, includ-
ing purine and thymidine synthesis [84]. Four polymorphisms in this gene were investigated
in six different studies [21,35,49–51,71]. One, rs2236225, was studied directly and associated
with MTX PK but with inconsistent results among the included studies [21,35,71]. One of the
studies noted an association between (GA and AA) variants and lowered 24 h MTX serum
concentration, but the observation did not pass the significance threshold (MTX AUC) after
correction for multiple comparisons [35]. The c.1958G > A, rs2236225 variant in MTHFD1
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has been associated with reduced histological response [85], but no significant effects were
observed in our study.
MTHFR
The enzyme methylenetetrahydrofolate reductase (MTHFR) is responsible for the
conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate which is needed
for the transformation of the toxic homocysteine to methionine (Figure 3). The enzyme is
expressed in most human cells but it is not directly involved in the transport of MTX [56].
It has been hypothesized that reduced expression of MTHFR would be associated with
MTX-induced toxicity in patients with leukemia but clinical studies show conflicting
results on this matter [86]. The T allele in SNP rs1801133 causes a change of alanine
to valine in the protein, resulting in decreased enzyme activity of MTHFR. Seven of
28 candidate gene studies found that the T allele in rs1801133 was associated with de-
creased elimination of MTX whereas no statistically significant association was found in
20 other studies [23,25–28,32–35,39,42,43,45–47,52,57,67,71–80]. The second most studied
SNP, rs1801131, was included in 17 candidate gene studies but none of these studies found
a clinically significant association between MTX elimination and this SNP.
MTR
5-methyltetrahydrofolate (5-methyl-THF) is a vitamin B12-dependent enzyme also
involved in the folate-mediated one-carbon metabolism. It catalyzes the methylation of ho-
mocysteine to methionine with the simultaneous conversion of 5-methyl-tetrahydrofolate
(5-methyl-THF) to tetrahydrofolate (THF) [56] (Figure 3). The variant rs1805087 within
MTR has previously been ascribed to toxicity outcomes. However, none of the reported
GWAS studies were able to establish an association between MTR and MTX PK. Several
candidate gene studies investigated rs1805087 for PK or toxicity measures and failed to
find any observable differences in concentration or AUC.
MTRR
5- methyltetrahydrofolate-homocysteine methyltransferase reductase (MTRR) is pri-
marily involved in the reductive methylation of homocysteine to methionine, utilizing
methylcobalamin as an intermediate methyl carrier [56] (Figure 3). Seven variants in
MTRR were examined. One particular variant, rs1801394, was tested in four separate
candidate gene studies [21,28,35,57]. However, only one of the four studies [28] found that
the rs1801394 (AG and GG) variants were associated with significantly lower 24 h MTX
concentrations as opposed to AA wild types. The study found no difference at the 48 h
MTX concentration, suggesting that variant rs1801394 G allele remains associated with
increased MTX clearance.
TYMS
The enzyme thymidylate synthase (TYMS) is essential for the de novo production of
purines in the DNA synthesis [87]. MTXPG inhibits the enzyme and thereby prevents the
transfer of one-carbon from 5,10-methylenetetrahydrofolate to deoxyuridine monophos-
phate (dUMP) in the formation of deoxythymidine monophosphate (dTMP) (Figure 3).
Low expression of TYMS in lymphoblastic leukemia cells is associated with decreased
antileukemic effects of MTX and increased risk of relapse [88]. TYMS is ubiquitously
expressed in normal human tissue, and thought to be important for basal cellular functions
but not directly involved in the transport of MTX [56]. The role of the enzyme in relation to
MTX-induced toxicity was examined in several candidate gene studies, which simultane-
ously searched for associations with MTX PK [25,33,34,42,43,46,57,71]. The most common
studied SNPs was rs34743033, known as the tandem repeat [25,33,34,42,43,46,57,71]. The
combination of increased TYMS expression (tandem repeat x3) and reduced function of
MTHFR (homozygous for the 677T allele) was associated with increased risk of MTX-
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induced hematologic toxicity but not plasma MTX concentrations [71]. Only two out of 14
studies found an association between SNPs in TYMS and MTX elimination [42,81].
3.3.3. Additional Genes Examined
Several additional genes were sparsely examined and do not fit into neither the folate
pathway nor transporter gene categories. ELMO1 [89], NALCN [89], NRII2 (SXR) [20],
SULT1E1 [90], UGT1A1 [46], and four intergenic polymorphisms [89] (rs3862227, rs4888024,
rs4905865, and rs1359645) were all found to significantly affect MTX PK. While significant,
these genes have only been reported once each. Replication would be needed in order to
definitively state that these genes do affect MTX PK. CCND1, CYP3A4, CYP3A5, GSTM1,
GSTP1, GSTT1, JAK1, JAK3, TPMT, TSG1, SHMT1, and VDR all failed to significantly affect
MTX PK, though rationale for their selection was often indirect of MTX PK.
4. Discussion
The large inter-individual variation in MTX clearance can only in part be explained
by differences in clinical patient characteristics and cancer treatment protocols. In this
systematic review, we evaluated 58 articles that studied the association between SNPs
and PK variables in relation to infusions with high-dose MTX. Most of these candidate
gene studies looked at the association between MTX PK parameters and common SNPs in
genes encoding transporter proteins (Table 1, Figure 2) or folate pathway genes (Table 2,
Figure 3), whereas rare non-synonymous mutations were less often included. The only
gene with variants influencing MTX PK was SLCO1B1, which is a bit surprising as it is
expressed in the liver, and the majority of MTX is eliminated through the kidney.
During and after a high-dose MTX infusion, the majority of MTX is eliminated through
the kidney, although enterohepatic circulation plays a substantial role. In vitro studies
have shown that several renal and hepatic transporter proteins have affinity for MTX,
and PK studies in knock-out mice have suggested that these transporters are involved in
the distribution and elimination of MTX [63,91,92]. Furthermore, cases of patients with
severely delayed MTX elimination have contributed to the idea that transporter proteins
and enzymes in the folate pathway can affect both MTX clearance and toxicity [93,94].
During a high-dose MTX infusion, the plasma concentration of MTX is probably so high
that most of the drug is eliminated by glomerular filtration. Hepatic uptake of MTX
probably affects the initial distribution of the drug, whereas active transport mediated
renal transporter proteins could play a more important role in eliminating MTX at low
plasma MTX concentrations.
Variants in the SLCO1B1 gene have been associated with increased clearance as well as
decreased clearance, and the phenotypes are well defined by the Clinical Pharmacogenetics
Implementation Consortium because it is the subject of a guideline for simvastatin. As of
this writing, the PharmVar consortium is working on renaming and consolidating alleles,
and will publish these in the future [95]. The evidence is building for utilizing SLCO1B1 in
dosing recommendations for MTX, though there is still a lot of variability between courses
of high-dose MTX that is not accounted for by these variants. One study showed variants
in this gene accounted for >10% of the between-subject variability, which was more than
clinical variables. Rare SLCO1B1 SNPs that negatively influence the cellular uptake of MTX
were also associated with low MTX clearance after infusions with high-dose MTX [51]. A
possible translation of this information into clinical changes could be that patients with
important SNPs in SLCO1B1 should receive closer monitoring with early measurement
of plasma MTX concentrations in order to optimize the supportive care (e.g., increased
hydration or urine alkalization) in case of decreased MTX clearance.
The other genes most studied were MTHFR and SLC19A1, but neither had a majority
of studies reporting significant associations. Overall, SLC19A1 is an important transporter
responsible for folate homeostasis. Folate is a crucial nutrient that supports important
physiological functions such as purine and pyrimidine biosynthesis and regulates the
production of one-carbon donors for DNA methylation. Evidence suggests that polymor-
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phisms in SLC19A1 increase the susceptibility to birth defects, which is why prenatal folate
supplementation is highly recommended. Mice lacking the Slc19a1 gene die in utero [96].
From an evolutionary perspective, damaging polymorphisms in SLC19A1 could have been
selected against to reduce the occurrence these abnormalities. As such, persisting polymor-
phisms in SLC19A1 may occur, but their effect on the transport functionality of SLC19A1
may be minimal. People with Down Syndrome have a third copy of SLC19A1, since it is
on chromosome 21. Patients with Down Syndrome treated with high-dose MTX are very
sensitive to toxicities and usually receive reduced doses, indicating that perhaps expression
but not genetic variants are associated with MTX-induced toxicities. MTHFR plays a central
role in folate metabolism by catalyzing the conversion of 5,10-methylenetetrahydrofolate
(THF) to 5-methylTHF. This is the primary circulating form of folate, which is needed to
reduce the toxic homocysteine to methionine. Through this process, folate is an important
donor of methyl-groups for all intracellular methylation processes. MTHFR—though an
important enzyme in intracellular folate metabolism—is not directly involved in MTX
transport or in the direct process of purine and pyrimidine synthesis. Based on the limited
significant findings and high volume of conflicting evidence, it is unlikely that polymor-
phisms in SLC19A1 and MTHFR significantly affect high-dose MTX PK in pediatric patients
with ALL, osteosarcoma, or lymphoma.
4.1. Toxicity
A decrease in MTX clearance, and thereby elevated MTX tissue exposure, potentially
leads to an increased risk of MTX-induced toxicity, although patients with elevated plasma
MTX concentrations receive additional folinic acid to rescue the normal tissue, which may
confound associations between MTX PK and toxicity. Furthermore, decreased function of
MTX transporter proteins or enzymes in the folate pathway can affect the intracellular han-
dling of MTX independently of plasma MTX levels and thereby lead to increased toxicity
despite normal systemic MTX clearance. Patients developing severe nephrotoxicity are at
risk of life-threatening MTX exposure requiring treatment with glucarpidase as a means
to enzymatically eliminate the drug. SNPs in SLCO1B1, MTHFR and SLC19A1 have been
studied extensively—with or without PK data—in relation to MTX-induced toxicity, mostly
in the pediatric ALL population. Only SLCO1B1 SNPs have been associated with MTX PK
and toxicity in a genome-wide association studies. SLCO1B1 rs4149056 (TT or TC geno-
type) and rs11045879 (CC and TC genotype) have been quite consistently associated with
decreased clearance and elevated MTX levels in combination with a lower frequency of
gastrointestinal toxicity and in a few cases with increased nephrotoxicity and hepatotoxic-
ity [25,29,33,38,49]. The association of MTHFR and SLC19A1 SNPs with toxicity is less clear.
MTHFR rs1801133 (C677T–CT or TT genotype) has been associated with increased MTX
levels and decreased MTX clearance [23,26,39,57,71,72,76,78]. However, an equal amount of
studies have failed to show this association [28,32,34,35,45–47,52,73–75,77,80]. In one study,
even when there was an association with higher MTX levels, a genetic association of this
SNP with renal toxicity could not be established suggesting that other clinical and genetic
factors play a role [23]. The most frequent toxicities associated with MTHFR rs1801133 were
mucositis and myelosuppression [57,72–74]. The role of SLC19A1 rs1051266/rs61510559
(G80A) in toxicity remains unclear. Many studies have reported no association between
this SNP and MTX PK [20,22,23,28,38,45] and others have shown contradicting results
showing both the AA as the GG variant associated with increased clearance [29,39–41].
SLC19A1 rs1051266/rs61510559 (G80A) has been associated with gastrointestinal toxicity
and hepatotoxicity [21,47]. Overall, data on MTX pharmacogenetics in relation to toxicity
have shown very inconsistent results and even when results were significant, effect sizes
were often small. This is often observed in pharmacogenomic studies of complex traits
such as the multifactorial process of developing MTX toxicity [97,98]. The transporter and
enzyme pathways of MTX are complex with many escape mechanisms. This and the fact
that patients differ in clinical characteristics hampers finding one single pharmacogenetic
variant to be associated with toxicity. It stresses the fact that PK measures, such as clearance
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and MTX levels, might be more effective in predicting toxicity than single pharmacogenetic
variants.
4.2. Limitations and Future Studies
In articles included in this review, most common SNPs in genes encoding transporter
proteins and enzymes in the folate pathway explain little or none of the inter-individual
variation in MTX elimination after infusions with high-dose MTX. Most of the studies
included were candidate gene studies, but there were three genome-wide association
studies. Genome-wide association studies rely on testing mostly intronic SNPs that are
in linkage disequilibrium (LD) with variants that affect function. LD is the association
among nearby DNA variations such that the alleles at neighboring polymorphisms are
connected within a population more frequently than if they were unlinked, and one needs
to only test one variant in the LD block to be fairly certain about the rest in the block.
The statistical power of genome-wide association studies and the ability to identify an
association between variation and phenotype depends on several factors, including the
frequency of the minor allele or genotype, the relevant risk given by the disease-associated
allele or genotype, the relationship between the genotyped marker and the minor allele,
size of the study, disease predominance, and genetic diversity in the population cohort [99].
Consequently, the method is limited to its ability to detect genetic association by LD. Most
of the studies in this review included less than 200 patients and as such did not have the
power to detect the impact of rare SNPs on MTX clearance or toxicity. Therefore, it would
be beneficial for future studies to investigate if rare SNPs significantly alter the function
of transporter proteins or enzymes in patients with severely delayed MTX elimination
or unexpected intense toxicity. Furthermore, future studies should consider replicating
and validating the select few genes with variants that significantly affected MTX exposure.
In recent years, machine learning (ML) has been an emerging branch of computational
methods that can enhance genome-wide association studies performance and interpretation
and identify new SNP associations. ML uses algorithms to build mathematical models
acquired from training on data and learning patterns. By combining data sources with
genotype, ML data are uniquely positioned to discover the hidden biological interactions
for better prediction and diagnosis of complex diseases [100].
5. Conclusions
In conclusion, in this extensive literature review, the only gene with the majority of
studies concluding that a variant influences MTX PK was SLCO1B1. A possible clinical
implication could be that patients with mutations in the SLCO1B1 gene putting them at risk
of decreased MTX clearance should receive closer monitoring with early measurement of
plasma MTX concentrations in order to optimize supportive care. Current studies are often
underpowered and unfit to study rare phenotypes with severely delayed MTX clearance
and rare non-synonymous mutations in relation to MTX PK parameters. Sequencing
outliers with severely delayed clearance may identify novel variants that have not been
discovered by genotyping previously. For future studies, collaboration to increase power is
essential.
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